Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2014

View Archived Issues

Gut-targeted anti-TNF polyclonal antibody granted U.S orphan status for pediatric ulcerative colitis

Milestone Pharmaceuticals reports phase I data for MSP-2017

In vivo data show strong antitumor activity of the novel FGFR/VEGR inhibitor ODM-203

Endo acquires rights to Natesto testosterone nasal gel

OncoSec and UCSF collaborate to study pembrolizumab and ImmunoPulse in metastatic melanoma

Orgenesis receives grant for autologous hepatocyte-derived therapy for type 1 diabetes

Low-affinity NMDA channel blockers could be useful for Rett syndrome

Adiponectin-like peptide agonist useful for hepatic fibrosis

Amarantus reports preclinical data on MANF in a model of retinitis pigmentosa

Antiviral drug discovery companies Cocrystal Pharma and RFS Pharma complete merger

Phase I results demonstrate safety of CTO plus bevacizumab in patients with malignant glioma

Researchers present in vivo data for a novel highly selective aldosterone synthase inhibitor

Antibe Therapeutics discloses HS-releasing prostaglandin inhibitor for acute pain

Interferon gene signature suppression with sifalimumab and anifrolumab in patients with SLE

Nordic Nanovector and Affibody collaborate on radioimmunotherapies for multiple myeloma

FDA requests additional data on daclatasvir in combination with other HCV drugs

Vargatef approved in E.U. for second-line treatment of NSCLC

Brd4 inhibitors prepared and tested at Gilead Sciences

Janssen patent describes compounds for HBV infection

Boehringer Ingelheim reports development of ACC2 inhibitors

Merck & Co. divulges HIV integrase inhibitors

FDA issues complete response letter for Avanir's AVP-825 for migraine

Spanish researchers describe HDAC inhibitors

Intra-Cellular Therapies initiates phase III trial of ITI-007 in schizophrenia

Regen BioPharma acquires cancer stem cell intellectual property from University of Toronto

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...